News Novartis/Ophthotech eye combo fails in phase 3 Lucentis and pegpleranib combination misses goal in wet AMD.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
